MicroRNA‑183 inhibits gastric cancer proliferation and invasion via directly targeting Bmi‑1

Xu,Lang; Li,Yuhong; Yan,Dan; He,Jun; Liu,Dan

doi:10.3892/ol.2014.2504

MicroRNA‑183 inhibits gastric cancer proliferation and invasion via directly targeting Bmi‑1

Authors:
- Lang Xu
- Yuhong Li
- Dan Yan
- Jun He
- Dan Liu
View Affiliations

Affiliations: Department of Pathology, Medical College, Wuhan University of Science and Technology, Wuhan 430065, P.R. China
Published online on: September 5, 2014 https://doi.org/10.3892/ol.2014.2504
Pages: 2345-2351

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aberrant expression of microRNA‑183 (miRNA/miR‑183) has been found to be involved in numerous tumor types. However, the role of miR‑183 in gastric cancer pathology is unclear and requires investigation. In the present study, the miR‑183 expression levels of gastric cancer cell lines and tissues obtained from gastric cancer patients were measured by reverse transcription quantitative polymerase chain reaction analysis. The effect of miR‑183 on gastric cancer cell proliferation and invasion was evaluated using MTT, colony formation and Transwell assays. The target of miR‑183 was identified and confirmed using a luciferase activity assay. The results revealed that miR‑183 was significantly downregulated in gastric cancer cells compared with GES‑1 normal gastric epithelial cells. In addition, miR‑183 was reduced in gastric cancer tissues compared with adjacent normal tissues. The ectopic expression of miR‑183 significantly inhibited gastric cancer cell proliferation, colony formation and invasion. Bmi‑1 was also confirmed as a downstream target of miR‑183 in the gastric cancer cells by western blot analysis and luciferase activity assays. In conclusion, miR‑183 is downregulated in gastric cancer cells and tissues, and inhibits gastric cancer cell proliferation and invasion by targeting Bmi‑1. Therefore, targeting miR‑183 may be a potential therapeutic strategy in gastric cancer patients.

View Figures

View References

1	Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011.
2	Houghton J, Stoicov C, Nomura S, et al: Gastric cancer originating from bone marrow-derived cells. Science. 306:1568–1571. 2004.
3	Zheng L, Wang L, Ajani J and Xie K: Molecular basis of gastric cancer development and progression. Gastric Cancer. 7:61–77. 2004.
4	Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 120:15–20. 2005.
5	Lee Y, Ahn C, Han J, et al: The nuclear RNase III Drosha initiates microRNA processing. Nature. 425:415–419. 2003.
6	Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005.
7	Ma L, Teruya-Feldstein J and Weinberg RA: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 449:682–688. 2007.
8	Yanaihara N, Caplen N, Bowman E, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 9:189–198. 2006.
9	Schaefer A, Jung M, Mollenkopf HJ, et al: Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 126:1166–1176. 2010.
10	Kim YK, Yu J, Han TS, et al: Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic Acids Res. 37:1672–1681. 2009.
11	Zhang J, Yang Y, Yang T, et al: microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity. Br J Cancer. 103:1215–1220. 2010.
12	Friedman JM, Jones PA and Liang G: The tumor suppressor microRNA-101 becomes an epigenetic player by targeting the polycomb group protein EZH2 in cancer. Cell Cycle. 8:2313–2314. 2009.
13	Kefas B, Godlewski J, Comeau L, et al: microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res. 68:3566–3572. 2008.
14	Marquez RT, Wendlandt E, Galle CS, Keck K and McCaffrey AP: MicroRNA-21 is upregulated during the proliferative phase of liver regeneration, targets Pellino-1, and inhibits NF-kappaB signaling. Am J Physiol Gastrointest Liver Physiol. 298:G535–G541. 2010.
15	Sun H, Li QW, Lv XY, et al: MicroRNA-17 post-transcriptionally regulates polycystic kidney disease-2 gene and promotes cell proliferation. Mol Biol Rep. 37:2951–2958. 2010.
16	Lowery AJ, Miller N, Dwyer RM and Kerin MJ: Dysregulated miR-183 inhibits migration in breast cancer cells. BMC Cancer. 10:5022010.
17	Zhao H, Guo M, Zhao G, et al: miR-183 inhibits the metastasis of osteosarcoma via downregulation of the expression of Ezrin in F5M2 cells. Int J Mol Med. 30:1013–1020. 2012.
18	Sarver AL, Li L and Subramanian S: MicroRNA miR-183 functions as an oncogene by targeting the transcription factor EGR1 and promoting tumor cell migration. Cancer Res. 70:9570–9580. 2010.
19	Liu K, Li G, Fan C, et al: Increased Expression of MicroRNA-221 in Gastric Cancer and Its Clinical Significance. J Int Med Res. 40:467–474. 2012.
20	Zhao X, Dou W, He L, et al: MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor. Oncogene. 32:1363–1372. 2013.
21	Li Z, Cao Y, Jie Z, et al: miR-495 and miR-551a inhibit the migration and invasion of human gastric cancer cells by directly interacting with PRL-3. Cancer Lett. 323:41–47. 2012.
22	Carvalho J, van Grieken NC, Pereira PM, et al: Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 up-regulation in intestinal gastric cancer. J Pathol. 228:31–44. 2012.
23	Gao P, Xing AY, Zhou GY, et al: The molecular mechanism of microRNA-145 to suppress invasion-metastasis cascade in gastric cancer. Oncogene. 32:491–501. 2013.
24	Zhu J, Feng Y, Ke Z, et al: Down-regulation of miR-183 promotes migration and invasion of osteosarcoma by targeting Ezrin. Am J Pathol. 180:2440–2451. 2012.
25	Ueno K, Hirata H, Shahryari V, et al: microRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer. Br J Cancer. 108:1659–1667. 2013.
26	Zhou T, Zhang GJ, Zhou H, Xiao HX and Li Y: Overexpression of microRNA-183 in human colorectal cancer and its clinical significance. Eur J Gastroenterol Hepatol. 26:229–223. 2014.
27	Zhu W, Liu X, He J, et al: Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: a case control study. BMC Cancer. 11:3932011.
28	Tanaka H, Sasayama T, Tanaka K, et al: MicroRNA-183 upregulates HIF-1alpha by targeting isocitrate dehydrogenase 2 (IDH2) in glioma cells. J Neurooncol. 111:273–283. 2013.
29	Kang MK, Kim RH, Kim SJ, et al: Elevated Bmi-1 expression is associated with dysplastic cell transformation during oral carcinogenesis and is required for cancer cell replication and survival. Br J Cancer. 96:126–133. 2007.
30	He S, Iwashita T, Buchstaller J, et al: Bmi-1 over-expression in neural stem/progenitor cells increases proliferation and neurogenesis in culture but has little effect on these functions in vivo. Dev Biol. 328:257–272. 2009.
31	Douglas D, Hsu JH, Hung L, et al: BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression. Cancer Res. 68:6507–6515. 2008.
32	Liu JH, Song LB, Zhang X, et al: Bmi-1 expression predicts prognosis for patients with gastric carcinoma. J Surg Oncol. 97:267–272. 2008.
33	Lu H, Sun HZ, Li H and Cong M: The clinicopathological significance of Bmi-1 expression in pathogenesis and progression of gastric carcinomas. Asian Pac J Cancer Prev. 13:3437–3441. 2012.